Dongkook Pharmaceutical said Monday it has signed a business agreement with Efil Bioscience to promote their joint research into new drugs.The two companies aim to develop promising new drugs, derive one or more non-clinical candidate substances by the end of this year, and conduct non-clinical rese
Pfizer Korea halted the supply of Vyndaqel Cap. 20 mg (Ingredient: Tafamidis), a transthyretin amyloid polyneuropathy (ATTR-PN) treatment, due to quality issues.The drug, which delays peripheral nerve damage in adult patients with stage 1 symptomatic polyneuropathy, has no substitute drug with the s
Ipsen Korea said it aims to provide a better treatment option for Korean renal cell cancer patients with a Cabometyx and Opdivo combination therapy after receiving approval to use the treatment as first-line therapy."Kidney cancer is a type of cancer difficult to detect at an early stage, and chemot
Dong-A ST said Friday that it has released non-clinical research results on the new drug candidate, DA-1726, in a poster session at the annual American Diabetes Association (ADA) conference.DA-1726 is a new drug under development as an oxyntomodulin analog-based obesity and diabetes treatment, which
Samsung Bioepis presented the phase 3 clinical trial results of its Soliris biosimilar, eculizumab (SB12), at the European Hematology Association 2022 (EHA2022) congress in Vienna on Friday.Soliris is a humanized monoclonal antibody produced in the NS0 cell line by recombinant DNA technology. It is
Sanofi-Aventis Korea’s labor union embarked on industrial action on Tuesday, as the wage negotiation with the management failed to narrow differences.According to the union, it has requested the management to reflect on the company’s improved sales performance last year on deciding this year’s wage
The European Medicines Agency (EMA) included Celltrion’s antibody treatment Regkirona (regdanvimab) in the list of critical medicines for Covid-19.EMA’s Medicines Shortages Steering Group (MSSG) adopted the list of critical drugs for the Covid-19 public health emergency on Tuesday, according to the
Eutilex said it would begin clinical trials for a CAR-T treatment to treat solid cancer for the first time in Korea.The company plans to submit an investigational new drug application (IND) for its CAR-T treatment pipeline in the second half of this year and has already secured non-clinical efficacy
Novartis said that the Ministry of Food and Drug Safety has approved Scemblix (Ingredient: asciminib), a treatment for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).Semblix treats adult patients with Ph+ CML in the chronic stages who have received treatment
Hanmi Pharmaceutical said Wednesday that the number of its drugs under development that have won orphan drug designations (ODD) has increased to 20, breaking its own record in the Korean biopharmaceutical industry.Most recently, Hanmi received an ODD from the European Medicines Agency (EMA) for LAPS
List Biotherapeutics, a U.S. subsidiary of Genome & Company, said that it has started the construction of its microbiome treatment production facility in Fishers City, Ind.Established in October 2020, List Biotherapeutics plans to build a large-scale microbiome production facility in Fishers Life Sc
Celltrion Pharmaceutical said it would exclusively market two diabetes treatment lineups – Nesina and Actos – it took over from Takeda Pharmaceutical. Jeil Pharmaceutical has marketed the two treatments.Celltrion has decided to end the joint sales contract at the end of this month and start direct s
Korea AI Center for Drug Discovery and Development (KAICD) said Wednesday that it would recruit expert instructors to develop and teach artificial intelligence (AI) to facilitate drug discovery and practical cooperative research.As an affiliated organization of the Korea Pharmaceutical and Bio-Pharm
The number of patients registered for phase 3 clinical trials of GNT Pharma’s stroke treatment, Nelonemdaz, has exceeded 100, raising expectations for completing all related trials in 2023 as scheduled, the company said Tuesday.Nelonemdaz is the first drug candidate worldwide that received approval
Amgen Korea and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha (evolucumab), lipid-lowering drugs for atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia starting in June.Under the agreement, Amgen Korea and Jeil Pharmaceutical will conduct Repatha sale
CHICAGO, Ill. – Lilly’s VEGRF2 inhibitor Cyramza (ramucirumab) in combination with Keytruda (pembrolizumab) proved a survival benefit, compared with the existing chemotherapy-based standard of care, in patients with non-small cell lung cancer (NSCLC) whose disease progressed after the first-line imm
CHICAGO, Ill. – Pfizer’s first CDK4/6 inhibitor Ibrance (palbociclib), failed to extend overall survival (OS) in the first breast cancer treatment in the phase 3 PALOMA-2 study.However, the PALOMA-2 study was not designed to check OS data, and it did not include some survival data of patients during
Samsung Bioepis presented new data on its adalimumab biosimilar, IMRALDI (SB5), at the European Alliance of Associations for Rheumatology (EULAR) 2022, in Copenhagen, Denmark, on Wednesday.The phase 1 clinical trial demonstrated pharmacokinetic (PK) equivalence between the new SB5 formulation and th
Hugel said Friday it obtained marketing approval for Letybo 50Unit, a botulinum toxin (BTX), from Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) on May 25.Earlier in 2019, Hugel and Austrian pharmaceutical firm Croma began phase 3 trials of the B
PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) could cure polycythemia vera (PV) fundamentally, the latest study results showed. Still, health experts said that Korean patients find it difficult to use it due to the lack of health insurance coverage.PharmaEssentia Korea held a symposium on